Sotera Health Company’s (NASDAQ:SHC) Q3 2026 sales top estimates, stock jumps 12.9%

Sotera Health (SHC) reported Q3 2026 revenue of $324.9M, beating estimates by 1.6%. Adjusted EPS was $0.29, an 8% beat. The company reconfirmed its full-year revenue and EPS guidance. Operating margin remained steady at 35.9%, while free cash flow margin improved to 17.8%.

Original reporting
Published Nov 3, 2026, 1:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 2:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Sotera Health Company’s (NASDAQ:SHC) Q3 2026 sales top estimates, stock jumps 12.9% — source image
Decision brief

The 30-second read

$SHCBullishMed
01

Why it matters

The combination of Q3 beats and reconfirmed FY guidance is a near-term positive catalyst, likely prompting analysts to adjust models and traders to reprice near-term expectations.

02

Market read

A same-day earnings print with guidance reconfirmation and a double-digit stock move makes this actionable for short-term positioning and expectation-setting.

03

What to watch

Free cash flow margin improved year over year, but the article does not break down drivers (working capital vs. operations), which could affect sustainability of the cash-flow trend.

Relevance 9/10Novelty 7/10Timing: post-earnings reaction, reported 2026-11-03 13:33 UTC

Background

The piece summarizes Sotera Health’s Q3 2026 results versus S&P analysts’ consensus and reiterates full-year guidance.

Company-level read

Ticker impact

$SHCBullishHigh confidence
Context

Sotera Health reported Q3 2026 revenue and adjusted EPS above consensus, and reconfirmed full-year guidance while shares jumped 12.9%.

Expected impact

Likely upward bias as the market digests the beat and treats the reconfirmed FY guidance as a credibility signal.

Evidence & confidence

The article provides specific Q3 beat figures and states management reconfirmed FY revenue and adjusted EPS guidance at the midpoint, aligning with the reported 12.9% jump.

Market effects

Supports sentiment for healthcare services providers with similar margin and cash-flow profiles, but no direct sector-wide catalyst is provided.

Primarily US-focused impact via a NASDAQ-listed issuer; no cross-market spillover details in the article.

Limited global relevance since the disclosure is company-specific and not tied to international policy or supply shocks.

Counterpoint

The article reconfirms guidance but does not show any upward revision, so the initial pop could fade if investors expected a raise.

Key entities

  • Sotera Health Company

    NASDAQ-listed healthcare services company reporting Q3 2026 results and reconfirming full-year guidance.

Related articles

MedAI 8/10

Sotera Health Company Q3 2026 Earnings Call Summary

Sotera Health reported Q3 2026 earnings, with Sterigenics and Nelson Labs driving performance. Nordion saw revenue decline due to cobalt-60 timing. Management noted European market softness. Guidance reaffirmed, with flat Q4 Sterigenics revenue and reduced 2027 CapEx. Nelson Labs' growth expected to moderate. Net leverage improved to 2.9x, leading to a credit rating upgrade. Litigation and FX headwinds noted.

$SHCHighAI 8/10

Sotera Health (SHC) Q3 2026 Earnings Call Transcript

Sotera Health (SHC) reported Q3 2026 revenue growth of 4.4% to $325M and adjusted EBITDA growth of 4% to $171M. Sterigenics grew 8.2%, Nelson Labs 9.2%, and Nordion declined 11.5%. The company reaffirmed its 2026 revenue and adjusted EBITDA outlook, expecting 5.25-6.75% and 5.75-7.25% growth, respectively. Adjusted EBITDA margins expanded sequentially by 100 basis points to 52.5%.

$SHCHighAI 8/10

Why is Sotera Health stock sliding today?

Sotera Health (SHC) shares fell 9.5% despite Q3 2026 earnings beat (EPS $0.29, revenue $324.9M) due to cautious guidance. Revenue declined 12% in the Nordion segment. JPMorgan downgraded to Underweight with a $17 target, and insiders sold 1.29M shares. The S&P 500 and Nasdaq rose, but Sotera's decline was company-specific.

$SHCMed

What Sotera Health (SHC) Said on Its Q3 Earnings Call

Sotera Health (SHC) reported Q3 earnings, noting softness in the European medical-device market. Sterigenics expects 6% constant-currency growth in Q4, while Nelson Labs saw 8.8% revenue growth. Nordion revenue fell 12.4% due to shipment timing. The company reaffirmed its 2026 outlook for 5.25% to 6.75% revenue growth and maintained its adjusted EBITDA forecast.